{"component": "definition", "props": {"groups": [{"size": 13, "snippet": "means a Drug Product that is manufactured pursuant to an NDA and Marketed in the United States under a name other than the proprietary name identified in the NDA.", "snippet_links": [{"key": "drug-product", "type": "definition", "offset": [8, 20]}, {"key": "pursuant-to", "type": "clause", "offset": [42, 53]}, {"key": "in-the-united-states", "type": "clause", "offset": [74, 94]}], "samples": [{"hash": "2AVVHOnlOSf", "uri": "https://www.sec.gov/Archives/edgar/data/1625297/000162529724000017/a425settlementagreementwst.htm", "label": "Indivior PLC", "score": 19.1765918732, "published": false}, {"hash": "hPzRBYjJiyJ", "uri": "https://www.sec.gov/Archives/edgar/data/1625297/000162828023020860/exhibit425-20xfa.htm", "label": "Indivior PLC", "score": 18.4236831665, "published": false}, {"hash": "4d861r6FWM6", "uri": "https://www.sec.gov/Archives/edgar/data/1625297/000162828023019402/exhibit45-20f.htm", "label": "Indivior PLC", "score": 18.3880901337, "published": false}], "hash": "6ac07fbf78eee508c6a6b19a92599a63", "id": 1}, {"size": 9, "snippet": "means a generic product indicated for the treatment of a human for multiple sclerosis that is therapeutically equivalent to, and substitutable for an Infringing Product by orally administering dimethyl fumarate, wherein the therapeutically effective amount of dimethyl fumarate is 480 mg per day, that is (a) sold by or on behalf of Licensee or any of Licensee\u2019s Affiliates, or its or their respective sublicensees, or (b) authorized by Licensee or any of Licensee\u2019s Affiliates or its or their respective sublicensees by license, covenant not to sue, settlement agreement, release or by any other arrangement or means (including with respect to ANDA filers) (i) for distribution in the U.S. under New Drug Application No. 204063 and/or any and all amendments or supplements thereto; or (ii) for distribution in a Designated Country.", "snippet_links": [{"key": "generic-product", "type": "definition", "offset": [8, 23]}, {"key": "treatment-of", "type": "definition", "offset": [42, 54]}, {"key": "multiple-sclerosis", "type": "clause", "offset": [67, 85]}, {"key": "therapeutically-equivalent", "type": "definition", "offset": [94, 120]}, {"key": "infringing-product", "type": "definition", "offset": [150, 168]}, {"key": "therapeutically-effective-amount", "type": "definition", "offset": [224, 256]}, {"key": "per-day", "type": "definition", "offset": [288, 295]}, {"key": "of-licensee", "type": "clause", "offset": [330, 341]}, {"key": "by-licensee", "type": "clause", "offset": [434, 445]}, {"key": "covenant-not-to-sue", "type": "definition", "offset": [530, 549]}, {"key": "settlement-agreement", "type": "definition", "offset": [551, 571]}, {"key": "other-arrangement", "type": "clause", "offset": [591, 608]}, {"key": "with-respect-to", "type": "clause", "offset": [629, 644]}, {"key": "for-distribution", "type": "clause", "offset": [662, 678]}, {"key": "the-us", "type": "clause", "offset": [682, 689]}, {"key": "application-no", "type": "clause", "offset": [706, 720]}, {"key": "amendments-or-supplements", "type": "clause", "offset": [748, 773]}, {"key": "designated-country", "type": "definition", "offset": [813, 831]}], "samples": [{"hash": "eD4Eup6i5NV", "uri": "/contracts/eD4Eup6i5NV#authorized-generic", "label": "Settlement and License Agreement", "score": 31.9111480713, "published": true}, {"hash": "enR3q0Clpjw", "uri": "https://ir.forward-pharma.com/static-files/67f6a24d-04b8-4e2a-9aa2-0674d8c2ddb2", "label": "ir.forward-pharma.com", "score": 9.9637231827, "published": false}, {"hash": "4ylSMGdM8iQ", "uri": "https://investors.biogen.com/static-files/a0cf3f2f-8b13-438c-8016-d86b73047e6b", "label": "investors.biogen.com", "score": 9.96235466, "published": false}], "hash": "f2973e46f4a6b7260434efe6394b6f0c", "id": 2}, {"size": 5, "snippet": "means any intranasal formulation of dihydroergotamine (other than Migranal) promoted or otherwise commercialized in the Territory by Valeant or its Affiliates, including without limitation, the intranasal dihydroergotamine mesylate product (4mg/mL nasal spray) promoted or otherwise commercialized in the Territory by Oceanside Pharmaceuticals, an Affiliate of Valeant.", "snippet_links": [{"key": "in-the-territory", "type": "clause", "offset": [113, 129]}, {"key": "including-without-limitation", "type": "clause", "offset": [160, 188]}, {"key": "nasal-spray", "type": "clause", "offset": [248, 259]}, {"key": "affiliate-of", "type": "definition", "offset": [348, 360]}], "samples": [{"hash": "lUn8iw7sN2x", "uri": "/contracts/lUn8iw7sN2x#authorized-generic", "label": "Co Promotion Agreement", "score": 31.3408622742, "published": true}, {"hash": "9yEo8Z2l9ed", "uri": "/contracts/9yEo8Z2l9ed#authorized-generic", "label": "Co Promotion Agreement (Zogenix, Inc.)", "score": 25.0355911255, "published": true}, {"hash": "bOHeJXKNbw4", "uri": "/contracts/bOHeJXKNbw4#authorized-generic", "label": "Co Promotion Agreement (Zogenix, Inc.)", "score": 24.6002731323, "published": true}], "hash": "718edfee55dba43447b5146624f4f835", "id": 3}, {"size": 5, "snippet": "means a Generic Version sold by or on behalf of a party hereto in the Territory, including by an Authorized Generic Distributor, but excluding by any ANDA Settlement Distributor.", "snippet_links": [{"key": "generic-version", "type": "clause", "offset": [8, 23]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [29, 47]}, {"key": "party-hereto", "type": "definition", "offset": [50, 62]}, {"key": "in-the-territory", "type": "clause", "offset": [63, 79]}, {"key": "authorized-generic-distributor", "type": "definition", "offset": [97, 127]}, {"key": "but-excluding", "type": "clause", "offset": [129, 142]}, {"key": "anda-settlement-distributor", "type": "definition", "offset": [150, 177]}], "samples": [{"hash": "gkudUX2KX9L", "uri": "/contracts/gkudUX2KX9L#authorized-generic", "label": "Commercialization Agreement (Salix Pharmaceuticals LTD)", "score": 25.5995883942, "published": true}, {"hash": "aHKZHEL8lK8", "uri": "/contracts/aHKZHEL8lK8#authorized-generic", "label": "Commercialization Agreement (Depomed Inc)", "score": 22.8480491638, "published": true}, {"hash": "3BDb4SNQJSG", "uri": "/contracts/3BDb4SNQJSG#authorized-generic", "label": "Commercialization Agreement (Santarus Inc)", "score": 22.8480491638, "published": true}], "hash": "e566f5f69ddfdf32f1225890cc187bc3", "id": 4}, {"size": 4, "snippet": "of a Brand-Name Drug means a drug product that: (a) is manufactured pursuant to (i) the NDA for the Brand-Name Drug, or (ii) an ANDA or a 505(b)(2) application for which the Brand-Name Drug is identified as the reference listed drug; and (b) is sold, offered for sale or distributed by\u2014or on behalf of\u2014 the holder of the NDA, but not sold or distributed under the proprietary name of the Brand-Name Drug.", "snippet_links": [{"key": "drug-product", "type": "definition", "offset": [29, 41]}, {"key": "pursuant-to", "type": "clause", "offset": [68, 79]}, {"key": "reference-listed-drug", "type": "definition", "offset": [211, 232]}, {"key": "offered-for-sale", "type": "definition", "offset": [251, 267]}, {"key": "on-behalf-of", "type": "clause", "offset": [289, 301]}, {"key": "the-holder", "type": "clause", "offset": [303, 313]}], "samples": [{"hash": "68r1CwHdJUK", "uri": "https://www.ftc.gov/system/files/documents/cases/151030concordiado.pdf", "label": "www.ftc.gov", "score": 8.8425731659, "published": false}, {"hash": "glL0Z4DXmQ7", "uri": "https://www.ftc.gov/system/files/documents/cases/151030pardo.pdf", "label": "www.ftc.gov", "score": 8.691991806, "published": false}, {"hash": "6VJRGNzxepO", "uri": "https://www.ftc.gov/system/files/documents/cases/150818concordiado.pdf", "label": "www.ftc.gov", "score": 5.8117728233, "published": false}], "hash": "921cdee684cf571663842eaefe364980", "id": 5}, {"size": 4, "snippet": "AG\u201d) drug\u201d means any drug sold, licensed or marketed under an NDA approved by the FDA under 21 U.S.C. \u00a7 355(c); and marketed, sold or distributed", "snippet_links": [{"key": "approved-by", "type": "definition", "offset": [66, 77]}, {"key": "the-fda", "type": "clause", "offset": [78, 85]}], "samples": [{"hash": "7ReDDaDfczF", "uri": "https://www.ftc.gov/sites/default/files/documents/reports/authorized-generic-drugs-short-term-effects-and-long-term-impact-report-federal-trade-commission/authorized-generic-drugs-short-term-effects-and-long-term-impact-report-federal-trade-commission.pdf", "label": "www.ftc.gov", "score": 10.1704311371, "published": false}, {"hash": "5YKLBkeZad4", "uri": "https://www.ftc.gov/system/files/filings/initiatives/223/genericspecialorders4-30-final.pdf", "label": "www.ftc.gov", "score": 3.0, "published": false}, {"hash": "1Kvlb8N4zkW", "uri": "https://www.ftc.gov/system/files/filings/initiatives/223/agspecialorders4-30-final.pdf", "label": "www.ftc.gov", "score": 3.0, "published": false}], "hash": "30ad2b6f71a9489f3d84a679d6a82812", "id": 6}, {"size": 4, "snippet": "shall have the meaning set forth in Section 6.9(e).", "snippet_links": [], "samples": [{"hash": "fO1jYho7Jf3", "uri": "/contracts/fO1jYho7Jf3#authorized-generic", "label": "Distribution Agreement (Osmotica Pharmaceuticals PLC)", "score": 29.7008895874, "published": true}, {"hash": "297f0V5DGMV", "uri": "/contracts/297f0V5DGMV#authorized-generic", "label": "Distribution Agreement (Osmotica Pharmaceuticals LTD)", "score": 29.6379184723, "published": true}, {"hash": "wj8dMnngGN", "uri": "/contracts/wj8dMnngGN#authorized-generic", "label": "Distribution Agreement (Osmotica Pharmaceuticals LTD)", "score": 29.5284061432, "published": true}], "hash": "fabc7a8e3620a5d1814c952d1b3b744c", "id": 7}, {"size": 4, "snippet": "means an unbranded, generic, finished, packaged form version of a Product approved or otherwise authorized for distribution in the Territory under the same applicable Marketing Authorization for the applicable Product.", "snippet_links": [{"key": "for-distribution", "type": "clause", "offset": [107, 123]}, {"key": "in-the-territory", "type": "clause", "offset": [124, 140]}, {"key": "marketing-authorization", "type": "definition", "offset": [167, 190]}, {"key": "applicable-product", "type": "definition", "offset": [199, 217]}], "samples": [{"hash": "fBCj5kncRVV", "uri": "/contracts/fBCj5kncRVV#authorized-generic", "label": "Stock and Asset Purchase Agreement (Bausch & Lomb Corp)", "score": 34.5112953186, "published": true}, {"hash": "hJrEaNbIrtx", "uri": "https://otp.tools.investis.com/generic/sec/sec-show.aspx?FilingId=16779540&Cik=0001860742&Type=PDF", "label": "otp.tools.investis.com", "score": 9.8391513824, "published": false}, {"hash": "4b4993cHKzW", "uri": "https://otp.tools.investis.com/clients/us/bausch_health_companies/sec/sec-show.aspx?FilingId=16779564&Cik=0000885590&Type=PDF&hasPdf=1", "label": "otp.tools.investis.com", "score": 9.8172483444, "published": false}], "hash": "d1ce9b35ee3c9208ef509ce95cf52aff", "id": 8}, {"size": 3, "snippet": "means a pharmaceutical product that would otherwise satisfy the requirements for a Generic Product under this Agreement, but which (a) is or will be manufactured, sold or otherwise distributed under the Product NDA and is (b) (i) manufactured, sold or otherwise distributed by a Third Party whose operations relating to such pharmaceutical product use rights received, directly or indirectly, from the Buyer pursuant to a license, settlement or other agreement or (ii) otherwise authorized, directly or indirectly, by the Buyer. For the avoidance of doubt, any pharmaceutical product that is manufactured, sold or otherwise distributed under an ANDA shall not be deemed to be an \u201cAuthorized Generic\u201d.", "snippet_links": [{"key": "pharmaceutical-product", "type": "clause", "offset": [8, 30]}, {"key": "requirements-for", "type": "clause", "offset": [64, 80]}, {"key": "generic-product", "type": "definition", "offset": [83, 98]}, {"key": "this-agreement", "type": "clause", "offset": [105, 119]}, {"key": "otherwise-distributed", "type": "definition", "offset": [171, 192]}, {"key": "product-nda", "type": "definition", "offset": [203, 214]}, {"key": "by-a-third-party", "type": "clause", "offset": [274, 290]}, {"key": "relating-to", "type": "definition", "offset": [308, 319]}, {"key": "product-use-rights", "type": "definition", "offset": [340, 358]}, {"key": "directly-or-indirectly", "type": "clause", "offset": [369, 391]}, {"key": "from-the-buyer", "type": "definition", "offset": [393, 407]}, {"key": "pursuant-to-a", "type": "definition", "offset": [408, 421]}, {"key": "agreement-or", "type": "definition", "offset": [451, 463]}, {"key": "by-the-buyer", "type": "clause", "offset": [515, 527]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [529, 555]}], "samples": [{"hash": "fwTWJY52eNS", "uri": "/contracts/fwTWJY52eNS#authorized-generic", "label": "Asset Purchase Agreement (Journey Medical Corp)", "score": 32.8056144714, "published": true}, {"hash": "3kSBPcjZMzX", "uri": "/contracts/3kSBPcjZMzX#authorized-generic", "label": "Asset Purchase Agreement (Journey Medical Corp)", "score": 32.6687202454, "published": true}, {"hash": "dTYNDuocIw6", "uri": "/contracts/dTYNDuocIw6#authorized-generic", "label": "Asset Purchase Agreement (Fortress Biotech, Inc.)", "score": 32.622177124, "published": true}], "hash": "6808dc9493e0583765be5d7cbeb9f5b7", "id": 9}, {"size": 3, "snippet": "means a pharmaceutical product that (i) is sold under the Regulatory Approval for a Product or Additional Product, (ii) is sold under a different Trademark than such Product or Additional Product, and (iii) has a National Drug Code (\u201cNDC\u201d) number that differs from the NDC number for such Product or Additional Product (other than on a temporary basis as may be necessary to launch such Product or Additional Product in the applicable market).", "snippet_links": [{"key": "pharmaceutical-product", "type": "clause", "offset": [8, 30]}, {"key": "regulatory-approval", "type": "definition", "offset": [58, 77]}, {"key": "additional-product", "type": "definition", "offset": [95, 113]}, {"key": "national-drug-code", "type": "definition", "offset": [213, 231]}, {"key": "ndc-number", "type": "definition", "offset": [269, 279]}, {"key": "temporary-basis", "type": "definition", "offset": [336, 351]}, {"key": "applicable-market", "type": "definition", "offset": [424, 441]}], "samples": [{"hash": "5Avf7BO4iR", "uri": "/contracts/5Avf7BO4iR#authorized-generic", "label": "License Agreement", "score": 31.3408622742, "published": true}, {"hash": "rXQPqffQoE", "uri": "/contracts/rXQPqffQoE#authorized-generic", "label": "License Agreement (Salix Pharmaceuticals LTD)", "score": 26.1170425415, "published": true}, {"hash": "6Ae0m4yH6Pj", "uri": "/contracts/6Ae0m4yH6Pj#authorized-generic", "label": "License Agreement (Santarus Inc)", "score": 23.1738529205, "published": true}], "hash": "df60057b604ddc4bcf5ac5a8ee0fa9bc", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIbYXV0aG9yaXplZC1nZW5lcmljIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 128, "snippet": "means a Drug Product that is manufactured pursuant to an NDA and Marketed in the United States under a name other than the proprietary name identified in the NDA.", "title": "Authorized Generic", "id": "authorized-generic", "examples": ["From and after the Effective Date until the earlier of (i) the termination of this Agreement, or (ii) a Generic Equivalent becomes available for sale in the Territory, Distributor shall not, and shall cause its Affiliates and SubDistributors to not, Market a Competing Product, other than a Cipher-supplied <strong>Authorized Generic</strong>, in the Territory.", "For purposes of clarity, except pursuant to Section 2.5, in no event shall Eagle, itself or through its Affiliates or any Third Party, launch any <strong>Authorized Generic</strong> version of a Product in the Territory.", "Santarus and its Affiliates shall pay to Shore [***] of the <strong>Authorized Generic</strong> Revenues received by Santarus and its Affiliates during the Term ***Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.", "Notwithstanding anything to the contrary, each of the diligence requirements set forth in this Section 5.1(b) shall terminate upon the first commercial sale of an <strong>Authorized Generic</strong> or Generic Equivalent.", "CHRP and Shore shall provide access to, and ensure that Santarus is able to use, (itself or on its behalf) the two (2) skid-mounted hot melt tanks and associated equipment (the \u201cTank Equipment\u201d) currently situated at Catalent in the manufacture of Licensed Products and <strong>Authorized Generic</strong> Products (as defined in the Impax Sublicense Agreement).", "Without limiting the foregoing, Sublicensor shall provide Sublicensee with not less than [*] ([*]) days\u2019 prior notice of the date on which any commercial scale quantities of an <strong>Authorized Generic</strong> Product are anticipated to be sold in the Territory.", "Notwithstanding the foregoing, in the event the parties launch an <strong>Authorized Generic</strong> of the Product (\u201cAG\u201d), the SMM Fee for such AG shall be seven and one-half (7.5%) of the Net Sales attributable to such AG for each twelve (12) month period, following the Commercial Launch of the AG.", "LICENSEE will send to the Council any and all verifiable evidence that a Third Party intends to launch a Generic Equivalent in the United States and will notify the Council promptly in writing in the event that LICENSEE or any of its Affiliates or sublicensees decides to use, distribute, sell, offer for sale, have sold and import Technology as an <strong>Authorized Generic</strong> Product in the Territory.", "Santarus, on behalf of itself and its Affiliates, hereby further covenants not to Commercialize, and not to permit or cause any licensee, sublicensee or other Third Party to Commercialize, an <strong>Authorized Generic</strong> version of a Product in the Territory, either directly or indirectly through a Third Party, until permitted under the provisions of the last paragraph of Section 2.1(a).", "In the event a Generic Product is launched, or a Competing Product is launched by Shire, in the Territory during the Services Term, the number of Prescriptions of such Generic Product and/or of any Competing Product launched by Shire shall be considered Prescriptions for the Shire Product in calculating the Gain Share Fees, provided, for clarity, that such calculation shall not include any Prescriptions of any <strong>Authorized Generic</strong> Product distributed by Impax."], "related": [["generic", "Generic", "Generic"], ["generic-name", "Generic name", "Generic name"], ["authorized-driver", "Authorized Driver", "Authorized Driver"], ["authorized-aftermarket-manufacturer", "Authorized aftermarket manufacturer", "Authorized aftermarket manufacturer"], ["commercial-product", "Commercial Product", "Commercial Product"]], "related_snippets": [], "updated": "2026-02-25T05:25:33+00:00"}, "json": true, "cursor": ""}}